Scientific Technology and R&D

Latest Development
The preclinical study results of IMM2902 published in "Drug Resistance Updates"

On February 16, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the research team of ImmuneOnco completed the preclinical study of IMM2902. The results were published in "Drug Resistance Updates" under the title "Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy".

Read more
The top medical Journal ‘Frontiers in Oncology’ published the preclinical study results of ImmuneOnco’s drug candidate IMM40H

On September 26, 2023,the R&D team of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) reported the preclinical research results of IMM40H under the tittle of ‘The Novel High-Affinity Humanized Antibody IMM40H Targets CD70, Eliminates Tumors Via Fc-mediated Effector Functions, and Interrupts CD70/CD27 Signaling’in the top journal Frontiers in Oncology’

Read more
ImmuneOnco published the preclinical research results of IMM47 in the journal "Antibody Therapeutics"

Recently, the R&D team of ImmuneOnco reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".

Read more
ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 AACR

On March 21, 2023, ImmuneOnco announced that the company will present the preclinical research data of IMM47 (CD24 antibody), IMM40H (CD70 antibody), IMM2520 (CD47×PD-L1), and IMM2902 (CD47×Her2) in the form of posters at the AACR 2023 Annual Meeting .

Read more